Navigation Links
IU researchers report first effective treatment of tumors arising from common genetic disease NF1

Physician-researchers at Indiana University School of Medicine have reported the first effective therapy for a class of previously untreatable and potentially life-threatening tumors often found in children.

Announcing their findings in the online first edition of Lancet Oncology, the researchers said the drug imatinib mesylate, marketed as Gleevec as a treatment for chronic myeloid leukemia, provided relief to a significant number of patients with plexiform neurofibromas, tumors caused by neurofibromatosis type 1, or NF1.

"Although this was a small study, the results were significant, particularly given that such patients have had few treatment options for what can be a very debilitating disease," said first author Kent Robertson, M.D., Ph.D., associate professor of pediatrics. "We believe these findings warrant larger trials of both imatinib mesylate as well as other similar compounds that would appear promising in laboratory tests."

Affecting about 1 in every 3,000 children born, NF1 is the most common neurological disorder caused by mutations in a single gene. Including a much rarer related type, NF2, neurofibromatosis is a genetic disorder that is more prevalent than cystic fibrosis, Duchenne muscular dystrophy and Huntington's disease combined, according to the Children's Tumor Foundation.

The mutation produces a variety of symptoms, from mild to severe. Patients can develop caf au lait spots and disfiguring tumors on or just under the skin. Internally, tumors can develop along nerve tissue and cause problems if they begin to press against vital organs or the windpipe. Some patients suffer from chronic pain.

The tumors have been nearly impossible to treat effectively. Because they are relatively slow growing, they are not affected by radiation treatments or cancer chemotherapy drugs. They also are often not good candidates for surgery because they are dangerously close to vital organs.

In the study reported in Lancet Oncology, of 23 patients who received the drug for at least six months, six experienced a 20 percent or more decrease in the volume of one or more plexiform neurofibromas, and 30 percent of patients had improvements in symptoms.

Primary investigator D. Wade Clapp, M.D., Richard L. Schreiner Professor and chairman of the Department of Pediatrics, noted that even relatively small reductions in tumor size can result in significant relief of symptoms for patients, such as improved breathing and restoration of bladder control.

In earlier laboratory research, the researchers determined that Gleevec was effective in tissue culture and mouse models of NF1 tumors after discovering that a cellular signaling mechanism that Gleevec targets in chronic myeloid leukemia also played an important role in development of NF1 tumors. Reporting that finding in the journal Cell in 2008, the research team also reported that in a compassionate use protocol, they had treated a 3-year-old girl with a life-threatening tumor compressing her airway. The girl's tumor shrank by half within three months of treatment.

Although Gleevec has been widely used as a treatment for chronic myeloid leukemia and has been prescribed in some cases for long periods without serious side effects, 13 of the initial 36 patients enrolled in the IU study dropped out before their results could be analyzed at six months of treatment. Nine of the 13 left due to problems taking the drug or side effects. The authors noted that they used the previously established maximum tolerated dose for Gleevec for this study to ensure that any drug activity against any NF1 tumors would be observed. This approach was taken among patients who had been living with slow-growing tumors for long periods of time and therefore were less likely to accept drug side effects than patients with malignant tumors, the authors suggested. Dosages have been modified in subsequent studies.


Contact: Eric Schoch
Indiana University

Related medicine news :

1. OHSU researchers discover potential way to repair brain damage in multiple sclerosis
2. Penn researchers find error reporting improves perceptions of safety and may reduce incidents
3. Common Antidepressants Too Risky During Pregnancy, Researchers Say
4. Mechanism found for destruction of key allergy-inducing complexes, Stanford researchers say
5. Feinstein Institute researchers discover that bean used in Chinese food could protect against sepsis
6. Mayo Clinic researchers develop new tools to better treat ADHD patients in early stages
7. Moffitt Researchers find genetic predictors of fatigue for some prostate cancer patients
8. Penn Medicine researchers map strategy for choosing wisely on low-value health care services
9. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
10. Moffitt researchers identify unique immune gene signature across thousands of patients solid tumors
11. Mount Sinai researchers identify predictors for inpatient pain
Post Your Comments:
Related Image:
IU researchers report first effective treatment of tumors arising from common genetic disease NF1
(Date:10/13/2015)... ... 2015 , ... According to an ESPN report published on October ... accidentally elbowed him in the left eye during the first day of practice for ... a series of setbacks, including a knee injury that has interfered with his ability ...
(Date:10/13/2015)... Irving, TX (PRWEB) , ... October 13, 2015 ... ... has tapped Dr. Bill Saye as the newest professional to introduce the latest ... Saye is highly recognized as a leading professional in Obstetrics and Gynecology and ...
(Date:10/13/2015)... ... October 13, 2015 , ... CVS/pharmacy, the retail division of ... enrolling and serving insurance consumers who do not have a bank account, which ... premiums. In “Health Plan Engagement Strategies: The ABCs of Serving Consumers Who Don’t ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... smoke-free communities, and the Florida Apartment Association (FAA) has partnered with the Florida ... communities meet the demand. , The FAA Smoke-Free Multifamily Housing Program launched ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Just under ... would-be customers, eMarketing Concepts began a $1 promotion – effectively offering all of their ... success, and within weeks the company was flooded with phone calls from interested buyers. ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... Apheresis is an invasive process that involves ... other components from whole blood. In this procedure, the blood ... apheresis machine or a blood cell separator. The apheresis equipment ... blood components. A selected part of the blood is removed, ... the patient. It involves the use of devices and disposables ...
(Date:10/12/2015)... Corporation (NASDAQ: LMNX ) today announced that it expects ... 2015 on Monday, November 2, 2015. A press release announcing ... trading. --> --> ... highlights and financial results for the third quarter ended September ... time. . Simply log on to ...
(Date:10/12/2015)... 2015 This study focuses on China,s ... the two past decades, the industry has been growing at ... and rising consumer consumptions in China ... China is one of the world,s ... economies in the world, China is ...
Breaking Medicine Technology: